Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
Astera Labs insider Philip Mazzara, the company's General Counsel and Secretary, reported sales of company common stock on 08/18/2025. The sales were automatic "sell-to-cover" transactions to satisfy tax withholding on vested restricted stock units and were not discretionary trades. The filing shows two grouped sales: 3,710 shares at a weighted average price of $183.8344 and 3,527 shares at a weighted average price of $183.1696, with per-share sale price ranges disclosed in each footnote. The reported post-transaction beneficial ownership balances are 175,100 and 171,573 shares respectively as shown on the form.
Astera Labs (ALAB) director and CEO Mohan Jitendra reported sales of common stock equal to 91,441 shares on 08/18/2025 at weighted-average prices near $183.8 and $183.17 per share. These sales were automatic "sell-to-cover" transactions to satisfy tax withholding on vested restricted stock units and were not discretionary trades by the reporting person. After the transactions the reporting person directly owned 2,170,877 shares. The filing also discloses multiple pools of indirectly owned shares held in various trusts and a living trust, each of which the reporting person disclaims beneficial ownership of except for any pecuniary interest.
Michael Truett Tate, Chief Financial Officer and Director of Astera Labs, Inc. (ALAB), reported routine insider transactions on Form 4. On 08/18/2025 he had automatic "sell-to-cover" sales of restricted stock units to satisfy tax withholding, selling 9,668 shares at a weighted-average price of $183.8343 and 9,193 shares at a weighted-average price of $183.1692. After those sales his direct beneficial ownership totals reported are 268,705 and 259,512 shares respectively. On 08/19/2025 he transferred 55,785 shares to the Tate 1997 Living Trust for no consideration and reported corresponding entries showing 203,727 shares held directly and 457,281 shares indirectly by the trust. The filing notes the transfers were non-discretionary sell-to-cover and the trustee disclaims beneficial ownership except for any pecuniary interest.
Astera Labs insider amendment reports multiple disposals and gifts of common stock by Michael Truett Tate, the companys CFO and trustee of the Tate Trust. The Form 4/A shows sales on 08/07/2025 and 08/08/2025: reported disposals include 43,184, 7,550, 15,141, and 34,125 shares sold at weighted-average prices ranging roughly from $169.05 to $174.04. The filing also records two bona fide gifts of 7,500 and 10,000 shares to non-affiliated recipients. Following the reported transactions the filing shows 501,496 shares beneficially owned indirectly by the Tate Trust. The amendment clarifies that a previously reported acquisition by GlobalStar Donor Advised Fund was an administrative error and that the Reporting Person has no pecuniary interest in that fund.
Astera Labs director Stefan A. Dyckerhoff reported insider transactions on 08/13/2025. The filing shows dispositions of common stock: 11,000 shares and 74,154 shares reported as sold. The form lists the reporting person as a director and indicates multiple indirect holdings held through trusts and a limited partnership.
The schedule reports 353,064 shares2,351 shares to be issued upon vesting of restricted stock units and that the reporting person disclaims beneficial ownership except for pecuniary interest.
Astera Labs CFO Michael Truett Tate reported multiple stock sales on 08/12/2025. The Form 4 shows dispositions of 66,561, 32,374 and 1,065 shares of common stock sold at weighted-average prices of approximately $190.8154, $191.9162 and $192.5156, respectively, and an additional 278,373 shares disposed, for a combined total of 378,373 shares sold on that date. Following the reported transactions, the filing lists beneficial ownership totals of 434,935, 402,561 and 401,496 shares in related entries, with indirect ownership noted by the Tate 1997 Living Trust and by GlobalStar DAF. The filing includes weighted price ranges for each sale series and a signature by an attorney-in-fact dated 08/14/2025. The reporting person disclaims beneficial ownership of trust- and DAF-held shares except for any pecuniary interest.
AllianceBernstein L.P. reports beneficial ownership of 6,391,580 shares of Astera Labs Inc common stock, representing 3.9% of the outstanding class. The filing states these shares are held for client discretionary investment advisory accounts and were acquired solely for investment purposes.
The submission provides a voting and dispositive-power breakdown: sole voting power for 6,157,426 shares, sole dispositive power for 6,390,751 shares and shared dispositive power for 829 shares. AllianceBernstein identifies as organized in Delaware and notes it is majority owned by Equitable Holdings, Inc. but operates under independent management; the filer certifies the holdings are in the ordinary course of business and not intended to influence control.
Astera Labs, Inc. (ALAB) filed a Form 144 notifying a proposed sale of 100,000 common shares with an aggregate market value of $19,118,990. The shares are to be sold on NASDAQ around 08/12/2025 through Morgan Stanley Smith Barney LLC. The filing lists 166,219,140 shares outstanding, so the proposed sale equals approximately 0.06% of outstanding shares.
The securities were acquired as founder stock on 09/11/2020. The filing also discloses recent sales by TATE 1997 LIVING TRUST: three tranches on 08/07/2025 totaling 100,000 shares for combined gross proceeds of $17,138,480.00, and a 05/30/2025 sale of 500,000 shares for $45,098,194.00. The filer attests they do not know any undisclosed material adverse information.
Astera Labs director Stefan A. Dyckerhoff reported multiple sales of company common stock on 08/07/2025 and 08/08/2025 totaling 52,000 shares. The filings show weighted-average sale prices in ranges reported between $172.50 and $175.86. Following the reported transactions one line reports direct beneficial ownership of 74,154 shares and the filing discloses substantial indirect holdings, including 364,064 shares held by a trust and several ~3,765-share holdings by named entities. The form notes 2,351 shares to be issued upon vesting of restricted stock units and includes standard disclaimers that certain partnership and trust holdings are disclaimed except for pecuniary interest. The Form 4 is signed and dated 08/11/2025.
Mohan Jitendra, Chief Executive Officer and director of Astera Labs (ALAB), reported sales of company common stock on 08/07/2025 executed under a Rule 10b5-1 trading plan adopted December 2, 2024. The Form 4 discloses a weighted average sale price of $170.3278 and lists lot-level price ranges and quantities for the transactions in a detailed footnote.
The filing also discloses amounts held indirectly by trusts: a Living Trust with 4,280,002 shares; a Trust with 699,999 shares; 2021 Trusts 1 and 2 with 700,000 shares each; and 2022 Trusts 1 and 2 with 450,001 shares each. The reporting person disclaims beneficial ownership of those trust holdings except to the extent of any pecuniary interest.